Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL1B | P01584 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 2/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25813731 | 0.94 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL27091569 | 0.93 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22326301 | 0.92 | CRBN (0.65) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29942770 | 0.91 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29098514 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30312865 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30312818 | 0.90 | CRBN (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25249480 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30312891 | 0.89 | CRBN (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29098530 | 0.89 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4107158-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020162725-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CRBN 4327/4885DDB1 3430/4885IKZF3 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.